Source link : https://www.newshealth.biz/health-news/upfront-tki-for-bone-predominant-rcc-tops-single-agent-immunotherapy/
LOUISVILLE, Ky. — Patients with bone-predominant metastatic renal cell carcinoma (RCC) appeared to have better outcomes when they started treatment with a targeted drug, results of a small retrospective review suggested. Median overall survival (OS) increased from 19.3 months with upfront immune checkpoint inhibition (ICI) to 41.3 months when a tyrosine kinase inhibitor (TKI) was […]
Author : News Health
Publish date : 2024-11-12 18:08:48
Copyright for syndicated content belongs to the linked Source.
